02
Sep

Ivabradine, a heart rate-reducing drug from Servier and Amgen, failed to beat placebo in a huge study of patients with coronary artery disease, potentially clouding its future on two continents.

…read more

Source: Servier and Amgen’s cardio drug faces uncertain future after trial flop

    

0 No comments